A. V. van Beek

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

BACKGROUND For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational gluc...

Normal dopamine uptake ratio on [18F]FDOPA pet-imaging in obesity.

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.

BACKGROUND AND AIMS In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this car...